Search
Advanced
HOME
MOLECULES
PROTEIN
MODULATOR
FEATURES
ALLO-HITtoLEAD
ALLO-PPI
DUALSTERIC-MODULATORS
ALLOSITE-POTENTIAL
ALLOSTEROME
ALLO-MUTATION
ALLO-DRUG
ALLO-NETWORK
SITE
PATHWAY
TOOLS
ALLO-REVERSE
DEEP-ALLODRIVER
ALLO-PHARM
ALLO-DRIVER
ALLO-FINDER
ALLO-SITE
ALLO-SCORE
ASBENCH
P-SEARCH
M-SEARCH
MISC
GLOSSARY
LITERATURE
EXPERT
LINKS
CONTACT
DOWNLOAD
STATISTICS
DOWNLOAD
HELP
Allo-Drug
Introduction of Allo-Drug
Allosteric drugs possess several distinct advantages over orthosteric drugs that bind to the same proteins, such as greater selectivity, fewer side effects, and lower toxicity. They have the potential to achieve greater selectivity to subtypes of proteins or highly structurally similar proteins. Thus, in recent years, vast energy has been invested in the discovery, optimization, and clinical development of allosteric drugs by the pharmaceutical industry. In the beginning, the allosteric drug design focused on GPCRs and kinases. After ten-years development, the range of target selection has already expanded to 14 protein categories. In ASD2019, we present all of the allosteric drug candidates in pre-clinical and clinical trial stages. In this dataset, 538 allosteric drugs, 96 allosteric targets from 14 protein categories, 187 disease conditions are all included. Among them, 18 allosteric drugs have earned approval from the U.S. Food and Drug Administration. This collection will provide the scientists an overview of allosteric drug discovery.
GO
Name
Loading...
Name
Loading...
Name
Loading...
Allosteric Drugs
Status
: All allosteric drugs
Page
of 1
Loading...
Page
of 1